| Ticker Details |
Spero Therapeutics, Inc.
Spero Therapeutics Inc is a multi asset clinical stage biopharmaceutical company. It is focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections.
|
| IPO Date: |
November 2, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$159.81M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.23 | 3.05%
|
| Avg Daily Range (30 D): |
$0.08 | 2.87%
|
| Avg Daily Range (90 D): |
$0.06 | 2.50%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.58M |
| Avg Daily Volume (30 D): |
.5M |
| Avg Daily Volume (90 D): |
.37M |
| Trade Size |
| Avg Trade Size (Sh.): |
248 |
| Avg Trade Size (Sh.) (30 D): |
136 |
| Avg Trade Size (Sh.) (90 D): |
154 |
| Institutional Trades |
| Total Institutional Trades: |
99 |
| Avg Institutional Trade: |
$1.67M |
| Avg Institutional Trade (30 D): |
$.54M |
| Avg Institutional Trade (90 D): |
$.59M |
| Avg Institutional Trade Volume: |
.19M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.03M |
| Avg Closing Trade (30 D): |
$1.11M |
| Avg Closing Trade (90 D): |
$1.11M |
| Avg Closing Volume: |
300.61K |
|
|
| Financials |
| |
TTM |
Q4 2025 |
FY 2025 |
|
Basic EPS
|
$-.13
|
$.56
|
$.15
|
|
Diluted EPS
|
$-.13
|
$.56
|
$.15
|
|
Revenue
|
$.26M
|
$41.3M
|
$66.8M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$-7.2M
|
$31.52M
|
$8.57M
|
|
Operating Income / Loss
|
$-7.54M
|
$31.41M
|
$6.31M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$15.86M
|
$-8.35M
|
$-12.62M
|
|
PE Ratio
|
|
|
|
|
|
|
